Lasa Supergenerics has reported results for fourth quarter and year ended March 31, 2022.
The company has reported over 3-fold jump in its net profit at Rs 12.28 crore for the quarter under review as compared to Rs 3.80 crore for the same quarter in the previous year. Total income of the company increased by 30.96% at Rs 51.22 crore for Q4FY22 as compared Rs 39.11 crore for the corresponding quarter previous year.
For the year ended March 31, 2022, the company has reported net loss of Rs 5.37 crore as compared to net profit of Rs 22.78 crore for the previous year. Total income of the company decreased by 32.24% at Rs 137.18 crore for year under review as compared to Rs 202.44 crore for year ended March 31, 2021.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: